Skip to content

Study · Randomized controlled trial · n = 71 · 1994

9 results

Treatment with the gonadotrophin releasing hormone-agonist goserelin before hysterectomy for uterine fibroids.

Lumsden MA, West CP, Thomas E, Coutts J, Hillier H, Thomas N, Baird DT

British journal of obstetrics and gynaecology1 May 1994Cited by 32 (Europe PMC)

PMID8018618 (opens in a new tab)DOI10.1111/j.1471-0528.1994.tb11919.x (opens in a new tab)PepBankPUB-08018618
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women undergoing hysterectomy for uterine leiomyomata, fibroid-related symptoms were lower with goserelin than placebo at operation.

    In plain wordsIn women with uterine fibroids, symptoms were lower with goserelin than placebo at surgery.

    Peptide
    Goserelin
    Outcome
    DecreaseFibroid-related symptoms
    Study

    n = 71

    Comparator
    Placebo sham injection
    Outcome group
    Fibroid Symptoms · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneous injection · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    At the time of operation, fibroid related symptoms were less in the goserelin group than in the placebo group.
    3 context sentences
    Summary · context
    Randomised placebo-controlled study.
    Summary · context
    Seventy-one premenopausal women with uterine leiomyomata who were on the waiting list for hysterectomy.
    Summary · context
    After the presence of leiomyomata was confirmed using ultrasonography, the women were randomised to receive either the GnRH-agonist goserelin by monthly subcutaneous injection or a sham injection for three months prior to operation.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with uterine leiomyomata, hysterectomy was technically easier after goserelin than placebo.

    In plain wordsIn women with uterine fibroids, hysterectomy was easier after goserelin than placebo.

    Peptide
    Goserelin
    Outcome
    DecreaseTechnical difficulty of hysterectomy
    Study

    n = 71

    Comparator
    Placebo sham injection
    Outcome group
    Surgical outcomes · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneous injection · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The hysterectomy was technically easier and the median (range) operative blood loss was significantly lower in the goserelin group compared with the placebo group (187 (60-600) ml vs 308 (118-1000) ml respectively; P < 0.05, Wilcoxon signed rank test).
    3 context sentences
    Summary · context
    Randomised placebo-controlled study.
    Summary · context
    Seventy-one premenopausal women with uterine leiomyomata who were on the waiting list for hysterectomy.
    Summary · context
    After the presence of leiomyomata was confirmed using ultrasonography, the women were randomised to receive either the GnRH-agonist goserelin by monthly subcutaneous injection or a sham injection for three months prior to operation.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with uterine leiomyomata, median operative blood loss was lower after goserelin than placebo (187 versus 308 ml, P < 0.05).

    In plain wordsIn women with uterine fibroids, blood loss during surgery was lower after goserelin than placebo.

    Peptide
    Goserelin
    Outcome
    DecreaseOperative blood loss
    Study

    n = 71

    Comparator
    Placebo sham injection
    Outcome group
    Surgical outcomes · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneous injection · 3 monthsAs given in this study (human).

    Measurements

    Blood loss
    187 ml
    goserelin median
    Blood loss
    60 to 600 ml
    goserelin range
    Blood loss
    308 ml
    placebo median
    Blood loss
    118 to 1000 ml
    placebo range

    Source sentences

    Summary
    The hysterectomy was technically easier and the median (range) operative blood loss was significantly lower in the goserelin group compared with the placebo group (187 (60-600) ml vs 308 (118-1000) ml respectively; P < 0.05, Wilcoxon signed rank test).
    3 context sentences
    Summary · context
    Randomised placebo-controlled study.
    Summary · context
    Seventy-one premenopausal women with uterine leiomyomata who were on the waiting list for hysterectomy.
    Summary · context
    After the presence of leiomyomata was confirmed using ultrasonography, the women were randomised to receive either the GnRH-agonist goserelin by monthly subcutaneous injection or a sham injection for three months prior to operation.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women undergoing hysterectomy for uterine leiomyomata, hospital stay did not differ between goserelin and placebo.

    In plain wordsIn women with uterine fibroids, hospital stay did not differ between goserelin and placebo.

    Peptide
    Goserelin
    Outcome
    No significant changeHospital stay
    Study

    n = 71

    Comparator
    Placebo sham injection
    Outcome group
    Surgical outcomes · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneous injection · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no difference between the two groups in the duration of hospital stay or the frequency of post-operative complications.
    3 context sentences
    Summary · context
    Randomised placebo-controlled study.
    Summary · context
    Seventy-one premenopausal women with uterine leiomyomata who were on the waiting list for hysterectomy.
    Summary · context
    After the presence of leiomyomata was confirmed using ultrasonography, the women were randomised to receive either the GnRH-agonist goserelin by monthly subcutaneous injection or a sham injection for three months prior to operation.
  5. 05HumanRandomized controlled trialSafety outcome

    In women undergoing hysterectomy for uterine leiomyomata, post-operative complication frequency did not differ between goserelin and placebo.

    In plain wordsIn women with uterine fibroids, complications after surgery did not differ between goserelin and placebo.

    Peptide
    Goserelin
    Outcome
    No significant changePost-operative complications
    Study

    n = 71

    Comparator
    Placebo sham injection
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneous injection · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no difference between the two groups in the duration of hospital stay or the frequency of post-operative complications.
    3 context sentences
    Summary · context
    Randomised placebo-controlled study.
    Summary · context
    Seventy-one premenopausal women with uterine leiomyomata who were on the waiting list for hysterectomy.
    Summary · context
    After the presence of leiomyomata was confirmed using ultrasonography, the women were randomised to receive either the GnRH-agonist goserelin by monthly subcutaneous injection or a sham injection for three months prior to operation.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women undergoing hysterectomy for uterine leiomyomata, fibroids were smaller after goserelin than placebo at operation.

    In plain wordsIn women with uterine fibroids, fibroids were smaller after goserelin than placebo at surgery.

    Peptide
    Goserelin
    Outcome
    DecreaseFibroid size
    Study

    n = 71

    Comparator
    Placebo sham injection
    Outcome group
    Tumor growth · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneous injection · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The fibroids were smaller at the time of operation in the goserelin group, and more women treated with goserelin were able to have their operations through a transverse incision.
    3 context sentences
    Summary · context
    Randomised placebo-controlled study.
    Summary · context
    Seventy-one premenopausal women with uterine leiomyomata who were on the waiting list for hysterectomy.
    Summary · context
    After the presence of leiomyomata was confirmed using ultrasonography, the women were randomised to receive either the GnRH-agonist goserelin by monthly subcutaneous injection or a sham injection for three months prior to operation.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In women with uterine leiomyomata, more goserelin-treated women than placebo-treated women could undergo surgery through a transverse incision.

    In plain wordsIn women with uterine fibroids, surgery through a transverse incision was possible more often after goserelin than placebo.

    Peptide
    Goserelin
    Outcome
    IncreaseTransverse incision feasibility
    Study

    n = 71

    Comparator
    Placebo sham injection
    Outcome group
    Surgical outcomes · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneous injection · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The fibroids were smaller at the time of operation in the goserelin group, and more women treated with goserelin were able to have their operations through a transverse incision.
    3 context sentences
    Summary · context
    Randomised placebo-controlled study.
    Summary · context
    Seventy-one premenopausal women with uterine leiomyomata who were on the waiting list for hysterectomy.
    Summary · context
    After the presence of leiomyomata was confirmed using ultrasonography, the women were randomised to receive either the GnRH-agonist goserelin by monthly subcutaneous injection or a sham injection for three months prior to operation.
  8. 08HumanNon-randomized trialEfficacy outcome

    In women awaiting hysterectomy for uterine leiomyomata, goserelin induced amenorrhoea in over 80%.

    In plain wordsIn women with uterine fibroids, goserelin stopped menstruation in over 80%.

    Peptide
    Goserelin
    Outcome
    Not applicableAmenorrhoea
    Study

    n: not reported in source

    Outcome group
    Menstrual Bleeding · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneous injection · 3 monthsAs given in this study (human).

    Measurements

    Amenorrhoea rate
    > 80%
    goserelin-treated women

    Source sentences

    Summary
    Treatment with goserelin induced amenorrhoea in over 80% of the women, and this was associated with a significant rise in haemoglobin level.
    3 context sentences
    Summary · context
    Randomised placebo-controlled study.
    Summary · context
    Seventy-one premenopausal women with uterine leiomyomata who were on the waiting list for hysterectomy.
    Summary · context
    After the presence of leiomyomata was confirmed using ultrasonography, the women were randomised to receive either the GnRH-agonist goserelin by monthly subcutaneous injection or a sham injection for three months prior to operation.
  9. 09HumanNon-randomized trialEfficacy outcome

    In women awaiting hysterectomy for uterine leiomyomata, goserelin-associated amenorrhoea accompanied a significant rise in haemoglobin.

    In plain wordsIn women with uterine fibroids, stopped menstruation during goserelin treatment accompanied a significant rise in haemoglobin.

    Peptide
    Goserelin
    Outcome
    IncreaseHaemoglobin
    Study

    n: not reported in source

    Outcome group
    Haematology · Whole body
    Studied dose
    Dose not stated · subcutaneous injection · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Treatment with goserelin induced amenorrhoea in over 80% of the women, and this was associated with a significant rise in haemoglobin level.
    3 context sentences
    Summary · context
    Randomised placebo-controlled study.
    Summary · context
    Seventy-one premenopausal women with uterine leiomyomata who were on the waiting list for hysterectomy.
    Summary · context
    After the presence of leiomyomata was confirmed using ultrasonography, the women were randomised to receive either the GnRH-agonist goserelin by monthly subcutaneous injection or a sham injection for three months prior to operation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.